Cornerstone Capital Management Holdings LLC. cut its holdings in Danaher Co. (NYSE:DHR) by 22.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 180,955 shares of the conglomerate’s stock after selling 52,644 shares during the quarter. Cornerstone Capital Management Holdings LLC.’s holdings in Danaher were worth $15,521,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Danaher by 1.3% during the second quarter. Vanguard Group Inc. now owns 41,488,407 shares of the conglomerate’s stock worth $3,501,206,000 after acquiring an additional 520,776 shares during the last quarter. BlackRock Inc. boosted its position in shares of Danaher by 3.2% in the second quarter. BlackRock Inc. now owns 39,201,798 shares of the conglomerate’s stock worth $3,308,239,000 after buying an additional 1,233,876 shares during the period. FMR LLC boosted its holdings in Danaher by 0.9% in the second quarter. FMR LLC now owns 19,624,350 shares of the conglomerate’s stock valued at $1,656,100,000 after purchasing an additional 183,183 shares during the last quarter. Parnassus Investments CA boosted its holdings in Danaher by 0.3% in the third quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock valued at $840,351,000 after purchasing an additional 29,381 shares during the last quarter. Finally, Flossbach Von Storch AG boosted its holdings in Danaher by 17.2% in the third quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock valued at $581,324,000 after purchasing an additional 994,902 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.
Shares of Danaher Co. (NYSE:DHR) traded down $0.38 during trading hours on Tuesday, reaching $92.44. 3,543,000 shares of the company’s stock traded hands, compared to its average volume of 2,020,000. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. The company has a market cap of $64,300.00, a PE ratio of 27.51, a PEG ratio of 2.19 and a beta of 1.02. Danaher Co. has a 52-week low of $77.66 and a 52-week high of $95.16.
Danaher (NYSE:DHR) last released its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.05. The firm had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The business’s revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.87 EPS. research analysts expect that Danaher Co. will post 3.99 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be paid a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a yield of 0.61%. The ex-dividend date is Thursday, December 28th. Danaher’s dividend payout ratio is presently 16.67%.
Several analysts have issued reports on DHR shares. Citigroup upped their price objective on Danaher to $107.00 and gave the company a “buy” rating in a research note on Friday, December 15th. Goldman Sachs Group restated a “neutral” rating and issued a $83.00 target price on shares of Danaher in a research report on Tuesday, September 26th. Credit Suisse Group increased their price target on Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a research note on Friday, October 20th. Robert W. Baird reaffirmed a “buy” rating and set a $99.00 price target on shares of Danaher in a research note on Friday, December 15th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating and set a $95.00 price objective on shares of Danaher in a research note on Friday, September 8th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Danaher has an average rating of “Buy” and a consensus target price of $94.38.
In other Danaher news, SVP Daniel Raskas sold 37,870 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total value of $3,534,407.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Donald J. Ehrlich sold 10,578 shares of the stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total transaction of $960,693.96. Following the completion of the transaction, the director now owns 104,621 shares of the company’s stock, valued at $9,501,679.22. The disclosure for this sale can be found here. Insiders have sold 273,810 shares of company stock valued at $25,218,813 in the last three months. 12.20% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “Danaher Co. (DHR) Stake Lessened by Cornerstone Capital Management Holdings LLC.” was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.truebluetribune.com/2018/01/03/cornerstone-capital-management-holdings-llc-sells-52644-shares-of-danaher-corporation-dhr.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.